Adult T-cell Leukemia (ATL)
Conditions
Interventions
None listed
Sponsors
University of the Ryukyus
NEC Corporation
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Cryopreserved plasma samples in the Okinawa HTLV-1/ATL Biobank (with consent for biological sample storage and use for future research) are used for this study. These samples were obtained from patients recruited from the following research projects: Establishment of the Okinawa HTLV-1/ATL Biobank, with University of the Ryukyus clinical ethics review no. 777, and Clinical Application of the Minute Residual Disease (MRD) in high-grade ATL patients, with University of the Ryukyus clinical ethics review no. 478
Exclusion criteria
Exclusion criteria: Participants withdrawing consent through opt-out forms available online at the homepage of the Laboratory of Hematoimmunology are excluded
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Calculation of p-values by t-test and discrimination capacities using AUC index, and setting of discrimination boundaries in multi-protein comparisons using machine learning algorithms, and ranking proteins based on AUC and significant values to detect candidate biomarker panel for ATL | — |
Secondary
| Measure | Time frame |
|---|---|
| Development a proteomic profile for ATL patients categorized according to ATL subtype (acute, chronic, smoldering, lymphoma) to search for ATL prognostic biomarkers; Development of a proteomic profile for ATL versus ATL in remission to search for ATL chemosensitivity biomarkers | — |
Countries
Japan
Contacts
Public ContactTakuya Fukushima
University of the Ryukyus School of Health Sciences, Faculty of Medicine, Laboratory of Hematoimmunology
Outcome results
None listed